20 articles
275-patient study tests novel liver-targeted therapy for NASH, a serious form of fatty liver disease affecting millions worldwide.
176-person trial tested whether pioglitazone could improve liver health by targeting insulin resistance in patients with fatty liver disease.
Major trial tests whether diabetes drug metformin can prevent frailty syndrome that affects millions of aging adults.
Enanta Pharmaceuticals tests its FXR agonist EDP-305 in a completed Phase 2 randomized trial for non-alcoholic steatohepatitis.
Mediterranean diet, resistance training, and diabetes medication combined to combat sarcopenia and improve metabolic health in older adults.
VA study tests whether combining lifestyle changes with metformin can reverse muscle loss and frailty in obese older adults.
Wake Forest study explores whether the diabetes drug metformin can trigger cellular changes linked to longevity in healthy people.
Czech study reveals how strategic fasting and ketogenic diets can reprogram harmful fat production in obesity.
Clinical trial tested whether metformin could improve surgical outcomes and reduce hospital stays in non-diabetic older patients.
Clinical trial tested whether metformin could enhance resistance training benefits for muscle mass and strength in older adults.
New study tests whether meal timing combined with Mediterranean diet can reverse fatty liver disease better than diet alone.
A completed trial investigates whether replenishing glutathione precursors can reverse metabolic dysfunction in elderly adults.
Columbia University tested whether the diabetes drug metformin could slow memory loss in people with mild cognitive impairment.
Phase 4 trial tests whether alirocumab can better control non-HDL cholesterol in high-risk type 2 diabetics failing statin therapy.
Eli Lilly's phase 3 trial pits a novel weekly basal insulin against the gold-standard daily insulin degludec in type 1 diabetes patients.
43 overweight adults followed intermittent fasting with 25% calorie reduction, measuring fat loss, muscle preservation, and metabolic changes.
Four-year study examined whether metformin could protect blood vessels in people with metabolic syndrome beyond its diabetes benefits.
Stanford study tests whether GLP-1 drug exenatide can restore insulin function and promote weight loss in people with prediabetes.
Turkish researchers tested whether adding high-fat, low-carb eating to intermittent fasting beats traditional IF for obesity treatment.
169-person study tests whether intermittent fasting and low-carb approaches can reverse insulin resistance and metabolic dysfunction.
